ANTI-EMETIC EFFECTS IN PATIENTS RECEIVING CARBOPLATIN–PACLITAXEL WITH OR WITHOUT BEVACIZUMAB CATEGORIZED AS MODERATELY EMETOGENIC CHEMOTHERAPY IN NON-SMALL-CELL LUNG CANCER

    loading  Checking for direct PDF access through Ovid

Abstract

Purpose

Palonosetron (PALO), a long-acting second-generation 5-hydroxytryptamine-3 receptor antagonist (5-HT3), and aprepitant (APR), neurokinin-1 receptor antagonist, were previously shown effective to prevent chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC). This study is to assess the antiemetic effects in the new generation anti-emetics group (NAg): using PALO, granisetron (GRA)–APR and PALO–APR, versus non-NAg: using GRA, on CINV caused by carboplatin (CBDCA)–paclitaxel (PTX) with or without bevacizumab (BV) categorized as MEC for the first time.

Methods

Clinical characteristics were retrospectively reviewed on 41 in-patients with non-small-cell lung cancer between January 2010 and December 2011. The clinical courses from days 1 to 5 of chemotherapy were observed.

Results

Anti-emetics administered in this study are NAg (21 cases: 3 are PALO, 4 are GRA–APR and 14 are PALO–APR) and non-NAg (20 cases). Dexamethasone on days 1–3 was in all cases. Complete response (CR: no nausea, no vomiting and no rescue medication) rates were significantly higher (P = 0.020) for NAg than non-NAg (85.7 and 50.0%, respectively).

Discussion

The results of this study indicate that NAg was significantly superior to CINV on CBDCA–PTX with or without BV.

Related Topics

    loading  Loading Related Articles